enovis - ENOV

ENOV

Close Chg Chg %
23.41 -0.63 -2.69%

Open Market

22.78

-0.63 (2.69%)

Volume: 66.47K

Last Updated:

Apr 29, 2026, 11:06 AM EDT

Company Overview: enovis - ENOV

ENOV Key Data

Open

$23.29

Day Range

22.54 - 23.29

52 Week Range

21.00 - 37.85

Market Cap

$1.34B

Shares Outstanding

57.30M

Public Float

56.26M

Beta

1.25

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$20.69

Yield

0.00%

Dividend

$16.67

EX-DIVIDEND DATE

Apr 5, 2022

SHORT INTEREST

N/A

AVERAGE VOLUME

804.75K

 

ENOV Performance

1 Week
 
-2.90%
 
1 Month
 
7.24%
 
3 Months
 
6.17%
 
1 Year
 
-33.71%
 
5 Years
 
-69.89%
 

ENOV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About enovis - ENOV

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

ENOV At a Glance

Enovis Corp.
2711 Centerville Road
Wilmington, Delaware 19808
Phone 1-302-252-9160 Revenue 2.25B
Industry Medical Specialties Net Income -1,182,531,000.00
Sector Health Technology 2025 Sales Growth 6.663%
Fiscal Year-end 12 / 2026 Employees 7,802
View SEC Filings

ENOV Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.676
Price to Book Ratio 1.023
Price to Cash Flow Ratio 7.00
Enterprise Value to EBITDA 9.635
Enterprise Value to Sales 1.275
Total Debt to Enterprise Value 0.481

ENOV Efficiency

Revenue/Employee 288,137.529
Income Per Employee -151,567.675
Receivables Turnover 5.077
Total Asset Turnover 0.526

ENOV Liquidity

Current Ratio 2.017
Quick Ratio 1.04
Cash Ratio 0.061

ENOV Profitability

Gross Margin 51.87
Operating Margin 0.134
Pretax Margin -51.574
Net Margin -52.603
Return on Assets -27.65
Return on Equity -58.369
Return on Total Capital -41.215
Return on Invested Capital -35.123

ENOV Capital Structure

Total Debt to Total Equity 92.608
Total Debt to Total Capital 48.081
Total Debt to Total Assets 35.975
Long-Term Debt to Equity 88.598
Long-Term Debt to Total Capital 45.999
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Enovis - ENOV

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.56B 1.71B 2.11B 2.25B
Sales Growth
-59.45% +9.22% +23.46% +6.66%
Cost of Goods Sold (COGS) incl D&A
825.72M 854.02M 1.08B 1.08B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
202.90M 217.10M 284.90M 294.40M
Depreciation
69.20M 76.90M 112.70M 109.90M
Amortization of Intangibles
133.70M 140.20M 172.20M 184.50M
COGS Growth
-65.64% +3.43% +26.60% +0.08%
Gross Income
737.38M 853.18M 1.03B 1.17B
Gross Income Growth
-49.19% +15.70% +20.31% +13.60%
Gross Profit Margin
+47.17% +49.98% +48.70% +51.87%
2022 2023 2024 2025 5-year trend
SG&A Expense
764.13M 857.95M 1.03B 1.12B
Research & Development
60.83M 75.33M 91.30M 120.33M
Other SG&A
703.30M 782.62M 938.89M 996.90M
SGA Growth
-31.45% +12.28% +20.07% +8.45%
Other Operating Expense
- - - 45.82M
-
Unusual Expense
(39.02M) 65.57M 768.49M 1.13B
EBIT after Unusual Expense
12.27M (70.34M) (772.22M) (1.12B)
Non Operating Income/Expense
10.61M 23.16M 7.00M 48.32M
Non-Operating Interest Income
200.00K 200.00K 600.00K 48.90M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
24.95M 19.95M 57.70M 83.72M
Interest Expense Growth
-66.09% -20.05% +189.24% +45.10%
Gross Interest Expense
24.95M 19.95M 57.70M 83.72M
Interest Capitalized
- - - -
-
Pretax Income
(2.07M) (67.13M) (822.92M) (1.16B)
Pretax Income Growth
-101.25% -3,144.47% -1,125.90% -40.89%
Pretax Margin
-0.13% -3.93% -39.05% -51.57%
Income Tax
36.12M (13.29M) 4.49M 22.29M
Income Tax - Current - Domestic
8.74M 5.13M 5.34M 2.35M
Income Tax - Current - Foreign
3.40M 9.00M 9.17M 22.17M
Income Tax - Deferred - Domestic
73.37M (22.87M) 1.79M (3.79M)
Income Tax - Deferred - Foreign
(49.39M) (4.55M) (11.80M) 1.57M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(38.19M) (53.84M) (827.42M) (1.18B)
Minority Interest Expense
1.53M 530.00K 679.00K 820.00K
Net Income
(39.72M) (54.37M) (828.10M) (1.18B)
Net Income Growth
-142.23% -36.87% -1,423.10% -42.80%
Net Margin Growth
-2.54% -3.18% -39.29% -52.60%
Extraordinaries & Discontinued Operations
- 24.73M 5.59M 2.60M
Discontinued Operations
- 24.73M 5.59M 2.60M
Net Income After Extraordinaries
(14.99M) (48.78M) (825.49M) (1.18B)
Preferred Dividends
- - - -
-
Net Income Available to Common
(14.99M) (48.78M) (825.49M) (1.18B)
EPS (Basic)
-0.2773 -0.8951 -14.9328 -20.7212
EPS (Basic) Growth
-118.21% -222.79% -1,568.28% -38.76%
Basic Shares Outstanding
54.07M 54.49M 55.28M 57.07M
EPS (Diluted)
-0.2773 -0.8951 -14.9328 -20.7212
EPS (Diluted) Growth
-118.47% -222.79% -1,568.28% -38.76%
Diluted Shares Outstanding
54.07M 54.49M 55.28M 57.07M
EBITDA
176.15M 212.33M 281.17M 297.41M
EBITDA Growth
-70.61% +20.53% +32.42% +5.78%
EBITDA Margin
+11.27% +12.44% +13.34% +13.23%

Snapshot

Average Recommendation BUY Average Target Price 44.20
Number of Ratings 11 Current Quarters Estimate 0.904
FY Report Date 06 / 2026 Current Year's Estimate 3.583
Last Quarter’s Earnings 0.826 Median PE on CY Estimate N/A
Year Ago Earnings 3.30 Next Fiscal Year Estimate 3.971
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 11 11 11
Mean Estimate 0.90 0.85 3.58 3.97
High Estimates 0.95 0.93 3.68 4.24
Low Estimate 0.87 0.80 3.20 3.54
Coefficient of Variance 2.91 5.21 3.65 4.44

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 10
OVERWEIGHT 1 1 1
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Enovis in the News